Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.

microscope

Infinity Pharmaceuticals Inc. had high expectations for the Phase II DYNAMO clinical trial testing its PI3K inhibitor duvelisib in indolent non-Hodgkin lymphoma (iNHL), but the company didn't sugarcoat the results: while the trial's primary endpoint was met, the data were not as good as hoped.

The results were so disappointing that Infinity and AbbVie Inc. are discussing potential changes to their partnership and Infinity...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip